Bloom Burton Issues Optimistic Forecast for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Bloom Burton boosted their Q3 2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a report released on Thursday, January 23rd. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.17 EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.69 EPS.

A number of other brokerages have also recently issued reports on MDP. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research note on Wednesday, January 8th. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Finally, Stifel Nicolaus boosted their price objective on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. One research analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$3.99 on Monday. The stock has a market capitalization of C$97.87 million, a P/E ratio of 79.80 and a beta of 1.96. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56. The firm’s 50 day simple moving average is C$3.33 and its two-hundred day simple moving average is C$2.75.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.